Reduction in membranous immunohistochemical staining for the intracellular domain of epithelial cell adhesion molecule correlates with poor patient outcome in primary colorectal adenocarcinoma

被引:7
作者
Wang, A. [1 ,2 ]
Ramjeesingh, R. [3 ]
Chen, C. H. [1 ,2 ]
Hurlbut, D. [1 ,2 ]
Hammad, N. [3 ]
Mulligan, L. M. [1 ,2 ]
Nicol, C. [1 ,2 ]
Feilotter, H. E. [1 ,2 ]
Davey, S. [1 ,2 ]
机构
[1] Queens Univ, Kingston Gen Hosp, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada
[2] Queens Univ, Kingston Gen Hosp, Dept Biomed & Mol Sci, Kingston, ON K7L 3N6, Canada
[3] Queens Univ, Kingston Gen Hosp, Dept Oncol, Kingston, ON K7L 3N6, Canada
关键词
Colon cancer; EPCAM; biomarkers; III COLON-CANCER; MONOCLONAL-ANTIBODY; EP-CAM; PROGNOSTIC-SIGNIFICANCE; RANDOMIZED-TRIAL; EPCAM EXPRESSION; ADJUVANT THERAPY; GENE-EXPRESSION; BREAST-CANCER; EDRECOLOMAB;
D O I
10.3747/co.23.3028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Epithelial cell adhesion molecule (EPCAM) is a multifunctional transmembrane glycoprotein expressed on both normal epithelium and epithelial neoplasms such as gastric, breast, and renal carcinomas. Recent studies have proposed that the proteolytic cleavage of the intracellular domain of EPCAM (EPCAM-ICD) can trigger signalling cascades leading to aggressive tumour behavior. The expression profile of EPCAM-ICD has not been elucidated for primary colorectal carcinoma. In the present study, we examined EPCAM-ICD immunohistochemical staining in a large cohort of patients with primary colorectal adenocarcinoma and assessed its performance as a potential prognostic marker. Methods Immunohistochemical staining for EPCAM-ICD was assessed on tissue microarrays consisting of 137 primary colorectal adenocarcinoma samples. Intensity of staining for each core was scored by 3 independent pathologists. The membranous EPCAM-ICD staining score was calculated as a weighted average from 3 core samples per tumour. Univariate analysis of the average scores and clinical outcome measures was performed. Results The level of membranous EPCAM-ICD staining was positively associated with well-differentiated tumours (p = 0.01); low preoperative carcinoembryonic antigen (p = 0.001); and several measures of survival, including 2-year (p = 0.02) and 5-year survival (p = 0.05), and length of time post-diagnosis (p = 0.03). A number of other variable-sincluding stage, grade, and lymph node status-showed correlations with EPCAM staining and markers of poor outcome, but did not reach statistical significance. Conclusions Low membranous EPCAM-ICD staining might be a useful marker to identify tumours with aggressive clinical behavior and potential poor prognosis and might help to select candidates who could potentially benefit from treatment targeting EPCAM.
引用
收藏
页码:E171 / E178
页数:8
相关论文
共 27 条
  • [1] [Anonymous], 2008, J CANC MOL
  • [2] EpCAM regulates cell cycle progression via control of cyclin D1 expression
    Chaves-Perez, A.
    Mack, B.
    Maetzel, D.
    Kremling, H.
    Eggert, C.
    Harreus, U.
    Gires, O.
    [J]. ONCOGENE, 2013, 32 (05) : 641 - 650
  • [3] Colacchio TA, 2004, J CLIN ONCOL, V22, p250S
  • [4] Prognostic Significance of EpCAM-Positive Disseminated Tumor Cells in Rectal Cancer Patients With Stage I Disease
    Dhayat, Sameer
    Sorescu, Sorina
    Vallboehmer, Daniel
    Kraus, Sebastian
    Baldus, Stephan Ernst
    Rehders, Alexander
    Kroepil, Feride
    Krieg, Andreas
    Knoefel, Wolfram Trudo
    Stoecklein, Nikolas Hendrik
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (12) : 1809 - 1816
  • [5] Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma
    Eichelberg, Christian
    Chun, Felix K.
    Bedke, Jens
    Heuer, Roman
    Adam, Meike
    Moch, Holger
    Terracciano, Luigi
    Hinrichs, Kristin
    Dahlem, Roland
    Fisch, Margit
    Schlomm, Thorsten
    Sauter, Guido
    Minner, Sarah
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (12) : 2948 - 2955
  • [6] Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer
    Fields, Anthony L. A.
    Keller, Alan
    Schwartzberg, Lee
    Bernard, Stephen
    Kardinal, Carl
    Cohen, Alan
    Schulz, Joe
    Eisenberg, Peter
    Forster, John
    Wissel, Paul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) : 1941 - 1947
  • [7] Expression of EpCAMMF and EpCAMMT variants in human carcinomas
    Fong, Dominic
    Seeber, Andreas
    Terracciano, Luigi
    Kasal, Armin
    Mazzoleni, Guido
    Lehne, Florian
    Gastl, Guenther
    Spizzo, Gilbert
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2014, 67 (05) : 408 - 414
  • [8] Lessons learned from the edrecolomab story: How a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy
    Goldberg, RM
    [J]. ONKOLOGIE, 2005, 28 (6-7): : 311 - 312
  • [9] Loss of membranous Ep-CAM in budding colorectal carcinoma cells
    Gosens, Marleen J. E. M.
    van Kempen, Leon C. L.
    van de Velde, Cornelis J. H.
    van Krieken, J. Han J. M.
    Nagtegaal, Iris D.
    [J]. MODERN PATHOLOGY, 2007, 20 (02) : 221 - 232
  • [10] An Ep-ICD Based Index Is a Marker of Aggressiveness and Poor Prognosis in Thyroid Carcinoma
    He, Helen C. -H.
    Kashat, Lawrence
    Kak, Ipshita
    Kunavisarut, Tada
    Gundelach, Raefe
    Kim, Dae
    So, Anthony K. -C.
    MacMillan, Christina
    Freeman, Jeremy L.
    Ralhan, Ranju
    Walfish, Paul G.
    [J]. PLOS ONE, 2012, 7 (09):